Earnings summaries and quarterly performance for Jade Biosciences.
Research analysts covering Jade Biosciences.
Recent press releases and 8-K filings for JBIO.
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. announced a private placement financing expected to generate approximately $45 million in gross proceeds.
- The company is selling 3,214,286 shares of its common stock at a price of $14.00 per share to BB Biotech.
- The private placement is expected to close on or about December 16, 2025.
- Net proceeds from the offering will be used to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:11 PM
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. (JBIO) has entered into a securities purchase agreement with BB Biotech for a private placement financing, expected to generate approximately $45 million in gross proceeds.
- The company is selling an aggregate of 3,214,286 shares of its common stock at a purchase price of $14.00 per share.
- The private placement is anticipated to close on or about December 16, 2025, subject to customary closing conditions.
- The net proceeds from this financing are intended to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:00 PM
Jade Management Discusses Clinical Pipeline and IgA Nephropathy Market
JBIO
New Projects/Investments
Product Launch
Guidance Update
- Jade (JBIO), founded in June 2024, is developing three assets, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), having initiated a Phase I study in August 2025 and expecting a key readout in H1 2026.
- The company's pipeline includes JADE201 (targeting BAFF-R) anticipated to enter the clinic in H1 2026, and a third undisclosed program in H1 2027.
- Jade is well-resourced to fund all trials into H1 2028.
- Management views IgA nephropathy as a a $10 billion+ opportunity in the US alone, emphasizing the disease-modifying potential of anti-APRIL therapies and the importance of convenience through infrequent dosing for JADE101.
- The FDA is considering shortening eGFR confirmatory trials for iGAN from two years to one year, which could support efficient development of anti-APRIL mechanisms.
Nov 17, 2025, 3:30 PM
JBIO Provides Update on Autoimmune Pipeline and IgA Nephropathy Market at Jefferies Conference
JBIO
New Projects/Investments
Product Launch
- JBIO, founded in June 2024, is developing best-in-class therapeutics for autoimmune diseases, with its lead program, JADE101, an anti-APRIL for IgA nephropathy (iGAN).
- The company initiated a Phase I healthy volunteer study for JADE101 in August 2025, with a key readout anticipated in the first half of 2026.
- JADE101 targets the iGAN market, estimated at over $10 billion in the US alone, and aims for best-in-class convenience with infrequent dosing.
- JBIO is well-resourced to fund its three pipeline programs into the first half of 2028.
- The second program, JADE201 (targeting BAFF-R), is expected to enter the clinic in the first half of 2026, with a third undisclosed program planned for the first half of 2027.
Nov 17, 2025, 3:30 PM
Jade Biosciences Reports Q3 2025 Financial Results and Corporate Updates
JBIO
Earnings
New Projects/Investments
- Jade Biosciences reported a net loss of $25.2 million for the third quarter ended September 30, 2025, compared to a net loss of $16.3 million for the same period in 2024.
- Research and Development (R&D) expenses increased to $22.0 million in Q3 2025 from $13.6 million in Q3 2024, while General and Administrative (G&A) expenses rose to $5.4 million from $1.4 million over the same periods.
- The company completed a $135 million private placement, which is expected to extend its cash runway into the first half of 2028.
- Significant pipeline progress includes the initiation of a Phase 1 healthy volunteer study for JADE101, with interim data anticipated in the first half of 2026, and the unveiling of JADE201, with its first-in-human trial expected to commence in the first half of 2026.
- As of September 30, 2025, Jade Biosciences held $198.9 million in cash, cash equivalents, and investments.
Nov 14, 2025, 12:00 PM
Jade Biosciences Updates on Pipeline Progress and Financial Position
JBIO
New Projects/Investments
Guidance Update
Convertible Preferred Issuance
- Jade Biosciences reported a pro forma cash position of $326 million as of October 2025, providing a financial runway into 1H 2028.
- The company is advancing three key programs: JADE101 (anti-APRIL for IgAN) with interim data expected in 1H 2026, JADE201 (anti-BAFF-R for autoimmune diseases) with planned First-in-Human (FIH) in 1H 2026, and JADE-003 (undisclosed) with planned FIH in 1H 2027.
- JADE101 targets the IgA nephropathy (IgAN) market, estimated at over $10 billion in the U.S. alone, and is designed for superior potency, extended half-life, and infrequent dosing.
- As of October 6, 2025, Jade Biosciences had 67,394,380 total outstanding shares, including common stock, preferred stock (as converted), and pre-funded warrants.
Nov 13, 2025, 11:00 PM
Jade Biosciences Discusses Lead Asset Jade 101 Development and Recent Financings
JBIO
New Projects/Investments
Debt Issuance
Convertible Preferred Issuance
- Jade Biosciences, founded last year, is developing Jade 101, an anti-APRIL therapeutic for IgA nephropathy (IgAN), targeting a Q8-week dosing interval or potentially longer.
- The company anticipates releasing Phase 1 healthy volunteer data for Jade 101 in the first half of 2026, with a focus on achieving maximal APRIL and IgA reductions.
- Jade Biosciences completed a reverse merger in April 2025, which included a $200 million PIPE and a $95 million convertible note, and subsequently closed an additional $135 million financing in October 2025.
- The FDA is exploring alternative, more efficient development pathways for IgAN therapies, which could potentially streamline Jade 101's path to market.
Nov 13, 2025, 8:00 PM
Jade Biosciences Secures Financing and Advances Autoimmune Therapies
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences has secured $135 million in additional gross proceeds, which is expected to support its cash runway into H1 2028.
- The company is advancing JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy (IgAN), with interim clinical data from its Phase 1 healthy volunteer trial anticipated in H1 2026. JADE101 is designed for high potency and infrequent dosing, targeting an estimated $10B+ branded market in the U.S. alone for IgAN.
- Jade's pipeline also includes JADE201, an anti-BAFF-R mAb with planned First-in-Human (FIH) studies in H1 2026 for multiple systemic autoimmune diseases, and JADE-003 with planned FIH in H1 2027.
- As of October 6, 2025, Jade Biosciences reported 67,394,380 total outstanding shares.
Nov 12, 2025, 11:00 PM
Jade Biosciences Provides Update on Pipeline Progress and Financial Position
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences, formed in June 2024, is focused on developing therapies for autoimmune diseases, with its lead program, JADE101 (an anti-APRIL for IgA nephropathy), having initiated a Phase I study with readout anticipated in the first half of 2025.
- The company's second program, JADE201 (a BAFF receptor antibody), is slated to begin its first trial in rheumatoid arthritis patients in the first half of next year.
- Jade Biosciences secured $300 million in April 2024 via a reverse merger and an additional $135 million from a PIPE in October 2024, extending its cash runway into the first half of 2028.
- JADE101 is designed for ultra-high binding affinity to APRIL and half-life extension, aiming for a convenient dosing schedule of no more than one injection every eight weeks.
Nov 12, 2025, 9:00 PM
Jade Biosciences Secures $135 Million Private Financing and Outlines Pipeline Advancement
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences announced a private financing of approximately $135 million in gross proceeds, which is expected to fund operations into 2028.
- The financing will support the clinical development of JADE one zero one, currently in Phase 1, with interim biomarker data anticipated in 2026, and its progression into late-stage IgAN patient trials.
- Funds will also advance JADE two zero one, a half-life extended monoclonal antibody targeting BAFR with a total addressable market of over $80 billion, into its first-in-human study in rheumatoid arthritis patients in 2026.
Oct 7, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more